Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Hematological Malignancies (3567)

Non-Hodgkin’s Lymphoma (922)

Hodgkin Lymphoma (59)

Hematological Malignancies (3567)

Non-Hodgkin’s Lymphoma (922)

Hodgkin Lymphoma (59)

›

No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	epcoritamab Sensitive: A1 - Approval FDA - 1 week (New A1) epcoritamab Sensitive : A1 FDA - 1wk	epcoritamab Sensitive: A1 - Approval FDA - 1 week epcoritamab Sensitive : A1 FDA - 1 week - (New A1)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week (New B) IMPT-314 Sensitive : B PRNewswire - 1wk	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week IMPT-314 Sensitive : B PRNewswire - 1 week - (New B)
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week (New B) IMPT-314 Sensitive : B PRNewswire - 1wk	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week IMPT-314 Sensitive : B PRNewswire - 1 week - (New B)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + zanubrutinib Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) rituximab + zanubrutinib Sensitive : A2 NCCN - 2wk	rituximab + zanubrutinib Sensitive: A2 - Guideline NCCN - 2 weeks rituximab + zanubrutinib Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + acalabrutinib Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) rituximab + acalabrutinib Sensitive : A2 NCCN - 2wk	rituximab + acalabrutinib Sensitive: A2 - Guideline NCCN - 2 weeks rituximab + acalabrutinib Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-Maxi-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-Maxi-CHOP Sensitive : A2 NCCN - 2wk	R-Maxi-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-Maxi-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAP + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-DHAP + R-CHOP Sensitive : A2 NCCN - 2wk	R-DHAP + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-DHAP + R-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAX + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-DHAX + R-CHOP Sensitive : A2 NCCN - 2wk	R-DHAX + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-DHAX + R-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAC + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-DHAC + R-CHOP Sensitive : A2 NCCN - 2wk	R-DHAC + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-DHAC + R-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials EHA 2023 - 2 weeks (New B) zanubrutinib Sensitive : B EHA 2023 - 2wk	zanubrutinib Sensitive: B - Late Trials EHA 2023 - 2 weeks zanubrutinib Sensitive : B EHA 2023 - 2 weeks - (New B)
PD-L1 expression	Diffuse Large B Cell Lymphoma	PD-L1 expression	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks (New C3) pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2wk	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2 weeks - (New C3)
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks (New C3) pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2wk	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2 weeks - (New C3)
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) acalabrutinib + KRT-232 Sensitive : C3 EHA 2023 - 2wk	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks acalabrutinib + KRT-232 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
LMO2 overexpression	T Cell Non-Hodgkin Lymphoma	LMO2 overexpression	T Cell Non-Hodgkin Lymphoma	fluzoparib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) fluzoparib Sensitive : C3 EHA 2023 - 2wk	fluzoparib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks fluzoparib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
LDH elevation	Non-Hodgkin’s Lymphoma	LDH elevation	Non-Hodgkin’s Lymphoma	ARI-0001 Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) ARI-0001 Resistant : C3 EHA 2023 - 2wk	ARI-0001 Resistant: C3 – Early Trials EHA 2023 - 2 weeks ARI-0001 Resistant : C3 EHA 2023 - 2 weeks - (New C3)
Chr del(17p)	Diffuse Large B Cell Lymphoma	Chr del(17p)	Diffuse Large B Cell Lymphoma	Immunotherapy Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) Immunotherapy Resistant : C3 EHA 2023 - 2wk	Immunotherapy Resistant: C3 – Early Trials EHA 2023 - 2 weeks Immunotherapy Resistant : C3 EHA 2023 - 2 weeks - (New C3)
TP53 deletion	Diffuse Large B Cell Lymphoma	TP53 deletion	Diffuse Large B Cell Lymphoma	Immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 EHA 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks Immunotherapy Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
ALK positive	T Cell Non-Hodgkin Lymphoma	ALK positive	T Cell Non-Hodgkin Lymphoma	brigatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) brigatinib Sensitive : C3 EHA 2023 - 2wk	brigatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks brigatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	crizotinib + LB-100 Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) crizotinib + LB-100 Sensitive : D EHA 2023 - 2wk	crizotinib + LB-100 Sensitive: D – Preclinical EHA 2023 - 2 weeks crizotinib + LB-100 Sensitive : D EHA 2023 - 2 weeks - (New D)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Lymphoma	No biomarker	Lymphoma	axicabtagene ciloleucel Resistant: A1 - Approval axicabtagene ciloleucel Resistant : A1	axicabtagene ciloleucel Resistant: A1 - Approval axicabtagene ciloleucel Resistant : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
CD20 expression	Non-Hodgkin’s Lymphoma	CD20 expression	Non-Hodgkin’s Lymphoma	rituximab-arrx Sensitive: A1 - Approval rituximab-arrx Sensitive : A1	rituximab-arrx Sensitive: A1 - Approval rituximab-arrx Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1

Lymphoma

Associations(1064)

Associations
(1064)